Lung Cancer Clinical Trial
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
Summary
The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung cancer.
Full Description
The patients on this study will receive treatment in 3 stages of therapy.
The first stage is Induction Therapy. This therapy is 7 weeks long. Patients will receive bevacizumab followed by pemetrexed followed by carboplatin all by vein once a week in weeks 1 and 4. During Induction patients will also receive radiation therapy daily, Monday through Friday, for 7 weeks (weeks 1-7). This is followed by 2 weeks of rest. During this rest period patients will have scans done to see how their disease has responded to treatment.
The next stage of treatment is Consolidation Therapy. This stage is 10 weeks long. Patients will receive bevacizumab followed by pemetrexed followed by carboplatin all by vein once a week in weeks 10, 13 and 16. This is followed by 3 weeks rest. During week 19 patients will have scans to see how their disease has responded to treatment.
The last stage of treatment is Maintenance Therapy. Patients will receive bevacizumab alone by vein every 3 weeks. Treatment will be given every three weeks for up to 9 treatments. (week 45)
Eligibility Criteria
Inclusion Criteria:
Clinically confirmed non-small cell lung cancer stage IIIA and selected stage IIIB
Measurable or evaluable disease
Be up and about and able to care for self
Adequate kidney, liver and bone marrow function
No prior treatment for this disease
Must be able to give written informed consent
Must be able to take folic acid, vitamin B12 and dexamethasone as described in the protocol
Age 18 years or older
Exclusion Criteria:
Stage IV or IIIB patients with pleural or pericardial effusions
Stage IIIB disease with contralateral mediastinal nodes greater than 4cm
Squamous cell predominant tumors
Pregnant or lactating women
Patients with active infections
History of another cancer within the last 5 years with the exception of skin cancer or cervical carcinoma in situ
History of stroke, transient ischemic attacks, or acute MI within the past 6 months or any other serious cardiovascular disease
Symptoms of peripheral vascular disease
History of neurological disease
Recent history of blood in the sputum or vomitus
Non-healing wounds, ulcer or long bone fractures
History of bleeding problems or coagulation problems
History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 6 months
History of uncontrolled hypertension
Chronic use of non-steroidal anti-inflammatory medication not allowed on this study
Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Gainesville Florida, 32605, United States
Lakeland Florida, 33805, United States
Marietta Georgia, 30060, United States
Louisville Kentucky, 40207, United States
Cincinnati Ohio, 45242, United States
Chattanooga Tennessee, 37404, United States
Nashville Tennessee, 37023, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.